SELLAS Life Sciences (SLS) Retained Earnings (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Retained Earnings of -$283.4 million for Q1 2026, down 11.6% year-over-year from -$320.6 million in Q1 2025, and down 3.06% quarter-over-quarter from -$275.0 million in Q4 2025.
SELLAS Life Sciences (SLS) Retained Earnings (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Retained Earnings for 17 consecutive years, with -$283.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 11.6% year-over-year to -$283.4 million; the TTM figure through Mar 2026 stood at -$283.4 million (down 11.6% YoY), while the FY2025 annual figure was -$275.0 million, down 10.83% from the prior year.
- Retained Earnings declined to -$283.4 million in Q1 2026 per SLS's latest filing, from -$275.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$155.3 million in Q1 2022 and bottomed at -$283.4 million in Q1 2026.
- Historically, Retained Earnings has averaged -$222.2 million across 5 years, with a median of -$226.8 million in 2024.
- Annual changes were most pronounced in 2022 — Retained Earnings sank 31.11% — and 2025, when it fell 10.73%.
- SELLAS Life Sciences' Retained Earnings stood at -$179.9 million in 2022, then retreated by 20.76% to -$217.2 million in 2023, then fell by 14.21% to -$248.1 million in 2024, then dropped by 10.83% to -$275.0 million in 2025, then fell by 3.06% to -$283.4 million in 2026.
- Business Quant data shows SLS's Retained Earnings at -$283.4 million in Q1 2026, -$275.0 million in Q4 2025, and -$267.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -293.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -293.00 Mn |
| Mar 31, 2026 | -283.40 Mn |
| Dec 31, 2025 | -274.99 Mn |
| Sep 30, 2025 | -267.30 Mn |
| Jun 30, 2025 | -260.54 Mn |
| Mar 31, 2025 | -253.94 Mn |
| Dec 31, 2024 | -248.13 Mn |
| Sep 30, 2024 | -241.40 Mn |
| Jun 30, 2024 | -234.28 Mn |
| Mar 31, 2024 | -226.80 Mn |
| Dec 31, 2023 | -217.24 Mn |
| Sep 30, 2023 | -209.10 Mn |
| Jun 30, 2023 | -199.80 Mn |
| Mar 31, 2023 | -191.00 Mn |
| Dec 31, 2022 | -179.90 Mn |
| Sep 30, 2022 | -170.80 Mn |
| Jun 30, 2022 | -163.76 Mn |
| Mar 31, 2022 | -155.30 Mn |
| Dec 31, 2021 | -138.60 Mn |
| Sep 30, 2021 | -132.01 Mn |